Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACMI - Accumed Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Dana Winrow who wrote (1580)	3/24/1998 9:35:00 AM
From: Frank Buck	Read Replies (1) \| Respond to of 1894

Cisco, Within the last couple of days AccuMed has swamped existing shareholders with a total of 8,686,666 shares more of ACMIC. For that substantial increase AccuMed has only netted a total of $5,910,000. There are almost 39% more shares outstanding as a result. Cognizant of the capital requirements to allow AccuMed to maintain their course objective, it seems like shareholders have had to pay twice for the ride they have been recently given. A reverse -split of 1-3 would not even put the shares outstanding @ below 10M. A 1-10 measure may take the outstanding volume to about the 3.? million share range....but the question now remains; Where will the price per share be after the shareholders adjustment for the new dilution takes effect? I can only assume that there are also no lock-ups on these new shares. Right now there are over 31 M shares outstanding...and the possibility for another almost 8.7 M shares when and if the warrants are exercised. For a grand total before reverse-split of 40 M. This ride has gotten way expensive. AccuMed is throwing the baby out with the bath water. Too bad they didn't take this measure in January before all of the deadlines and such. The first quarter is shot and we don't even know about the previous quarters revenues.... which won't make a difference because of the impending sell-off of the molecularbiology lines. AccuMed will then have the $$$ to buy out the 1/3 remaining interest of the Savant from Oncometrics. Sakura it seems has wound up owning a piece of what they originally wanted and can own more of it for .75 cents per share (pre reverse split). What's your take? Frank